GlobeNewswire Inc | Nov 22, 2021 07:30AM EST

November 22, 2021

BOSTON, Nov. 22, 2021 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE), a biotechnology company developing novel molecular glue degrader medicines, today announced members of its management team will be participating in the Piper Sandler 33rd Annual Virtual Healthcare Conference from Nov. 30-Dec. 2, 2021. The companys pre-recorded fireside chat is available for registered attendees via the Piper Sandler conference site from Nov. 22-Dec. 2.

An archived webcast of the fireside chat can be accessed via the Events & Presentations section of the companys investor site at https://ir.monterosatx.com/.

About Monte RosaMonte Rosa Therapeutics is a biotechnology company developing a portfolio of novel molecular glue degrader medicines. These medicines are designed to employ the bodys natural mechanisms to selectively eliminate therapeutically relevant proteins. The company has developed a proprietary protein degradation platform, called QuEEN(Quantitative andEngineeredElimination ofNeosubstrates), that enables it to rapidly identify protein targets and molecular glue degrader, or MGD, product candidates that are designed to eliminate therapeutically relevant proteins in a highly selective manner. The companys drug discovery platform combines diverse and proprietary chemical libraries of small molecule protein degraders with in-house proteomics, structural biology, AI/machine learning-based target selection and computational chemistry capabilities to predict and obtain protein degradation profiles. For more information, visit www.monterosatx.com.

Contacts:

InvestorsMichael Morabito, Solebury Troutir@monterosatx.com

MediaDan Budwick, 1ABdan@1abmedia.com